期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
中药复方的现代基础研究进展述评
1
作者 杨洪军 李贤煜 +6 位作者 陈鹏 张晶晶 吴宏伟 郭娜 郭非非 廖星 毕明刚 《中国科学基金》 CSCD 北大核心 2024年第3期387-395,共9页
中药复方的现代基础研究是中药现代化发展的必经之路。本文从中药复杂作用模式解析研究策略与方法、中药直接靶点发现技术与应用、系统生物学驱动的中药复杂作用解析三个方面,对中药复方的现代基础研究进行综述,并对其未来发展进行展望。
关键词 中药复方 现代基础研究 靶点发现 系统生物学 复杂作用解析
下载PDF
Manufacturing CAR-NK against tumors: Who is the ideal supplier?
2
作者 feifei guo Yi Zhang Jiuwei Cui 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第1期1-16,共16页
Chimeric antigen receptor-natural killer(CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compen... Chimeric antigen receptor-natural killer(CAR-NK) cells have emerged as another prominent player in the realm of tumor immunotherapy following CAR-T cells. The unique features of CAR-NK cells make it possible to compensate for deficiencies in CAR-T therapy, such as the complexity of the manufacturing process, clinical adverse events, and solid tumor challenges. To date, CAR-NK products from different allogeneic sources have exhibited remarkable anti-tumor effects on preclinical studies and have gradually been applied in clinical practice.However, each source has advantages and disadvantages. Selecting a suitable source may help maximize CAR-NK cell efficacy and increase the feasibility of clinical transformation. Therefore, this review discusses the development and challenges of CAR-NK cells from different sources to provide a reference for future exploration. 展开更多
关键词 CAR-NK cells cord blood IPSC NK-92 cells peripheral blood
下载PDF
Hypoxic tumor microenvironment:Destroyer of natural killer cell function
3
作者 Yongfei Zhang feifei guo Yufeng Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2024年第2期138-150,共13页
In recent years, immunotherapy has made remarkable progress in treating certain tumors and hematological malignancies. However, the efficacy of natural killer(NK) cells, which are an important subset of innate lymphoc... In recent years, immunotherapy has made remarkable progress in treating certain tumors and hematological malignancies. However, the efficacy of natural killer(NK) cells, which are an important subset of innate lymphocytes used in anticancer immunotherapy, remains limited. Hypoxia, a critical characteristic of the tumor microenvironment(TME), is involved in tumor development and resistance to radiotherapy, chemotherapy, and immunotherapy. Moreover, hypoxia contributes to the impairment of NK cell function and may be a significant factor that limits their therapeutic effects. Targeted hypoxia therapy has emerged as a promising research area for enhancing the efficacy of NK cell therapy. Therefore, understanding how the hypoxic TME influences NK cell function is crucial for improving antitumor treatment outcomes. 展开更多
关键词 HYPOXIA IMMUNOTHERAPY NK cell tumor microenvironment
下载PDF
Immune evasion and therapeutic opportunities based on natural killer cells 被引量:3
4
作者 Jinjin Zhang feifei guo +2 位作者 Lingyu Li Songling Zhang Yufeng Wang 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2023年第3期283-298,共16页
Natural killer(NK)cells can elicit an immune response against malignantly transformed cells without recognizing antigens,and they also exhibit cytotoxic effects and immune surveillance functions in tumor immunotherapy... Natural killer(NK)cells can elicit an immune response against malignantly transformed cells without recognizing antigens,and they also exhibit cytotoxic effects and immune surveillance functions in tumor immunotherapy.Although several studies have shown the promising antitumor effects of NK cells in immunotherapy,their function is often limited in the tumor microenvironment because tumor cells can easily escape NK cell-induced death.Thus,for efficient tumor immunotherapy,the mechanism by which tumor cells escape NK cell-induced cytotoxicity must be fully understood.Various novel molecules and checkpoint receptors that mediate the disruption of NK cells in the tumor microenvironment have been discovered.In this review,we analyze and detail the major activating and inhibitory receptors on the surface of NK cells to delineate the mechanism by which tumor cells suppress NKG2D ligand expression and increase tumor receptor and inhibitory receptor expression[NKG2A,programmed cell death1(PD-1),and T-cell immunoglobulin and immunoreceptor tyrosine inhibitory motif(TIGIT)]on the NK cell surface,and thus inhibit NK cell activity.We also reviewed the current status of treatments based on these surface molecules.By comparing the therapeutic effects related to the treatment status and bypass mechanisms,we attempt to identify optimal single or combined treatments to suggest new treatment strategies for tumor immunotherapy. 展开更多
关键词 Immune evasion natural killer cell NKG2D PD-1 combination therapy
下载PDF
CAR-T细胞治疗实体瘤的现存挑战及优化策略 被引量:3
5
作者 郭菲菲(综述) 崔久嵬(审校) 《中国肿瘤临床》 CAS CSCD 北大核心 2022年第12期617-621,共5页
近年来,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在血液肿瘤治疗中取得了突破性进展。然而,由于实体瘤异于血液肿瘤的特性,CAR-T在实体瘤治疗中并未取得很好的疗效。限制CAR-T疗效的关键因素主要包括实体瘤细胞... 近年来,嵌合抗原受体T细胞(chimeric antigen receptor T-cell,CAR-T)疗法在血液肿瘤治疗中取得了突破性进展。然而,由于实体瘤异于血液肿瘤的特性,CAR-T在实体瘤治疗中并未取得很好的疗效。限制CAR-T疗效的关键因素主要包括实体瘤细胞本身及其特殊的肿瘤微环境(tumor microenvironment,TME)两方面,在CAR-T向肿瘤组织部位浸润、CAR-T在TME中维持抗肿瘤活性以及CAR-T对肿瘤细胞的靶向性识别杀伤等多个过程中损害CAR-T功能。为了解决这些问题,越来越多的临床前研究提出了潜在有效的解决办法,相应的临床研究也相继开展。本文将对CAR-T细胞治疗实体瘤的现存挑战及相应的优化策略进行综述,以期为CAR-T疗法的未来探索提供参考。 展开更多
关键词 嵌合抗原受体T细胞 实体瘤 治疗策略
下载PDF
Exploration of Target Spaces in the Human Genome for Protein and Peptide Drugs
6
作者 Zhongyang Liu Honglei Li +8 位作者 Zhaoyu Jin Yang Li feifei guo Yangzhige He Xinyue Liu Yaning Qi Liying Yuan Fuchu He Dong Li 《Genomics, Proteomics & Bioinformatics》 SCIE CAS CSCD 2022年第4期780-794,共15页
After decades of development,protein and peptide drugs have now grown into a major drug class in the marketplace.Target identification and validation are crucial for the discovery of protein and peptide drugs,and bioi... After decades of development,protein and peptide drugs have now grown into a major drug class in the marketplace.Target identification and validation are crucial for the discovery of protein and peptide drugs,and bioinformatics prediction of targets based on the characteristics of known target proteins will help improve the efficiency and success rate of target selection.However,owing to the developmental history in the pharmaceutical industry,previous systematic exploration of the target spaces has mainly focused on traditional small-molecule drugs,while studies related to protein and peptide drugs are lacking.Here,we systematically explore the target spaces in the human genome specifically for protein and peptide drugs.Compared with other proteins,both successful protein and peptide drug targets have many special characteristics,and are also significantly different from those of small-molecule drugs in many aspects.Based on these features,we develop separate effective genome-wide target prediction models for protein and peptide drugs.Finally,a user-friendly web server,Predictor Of Protein and Pept Ide drugs’therapeutic Targets(POPPIT)(http://poppit.ncpsb.org.cn/),is established,which provides not only target prediction specifically for protein and peptide drugs but also abundant annotations for predicted targets. 展开更多
关键词 Protein drug Peptide drug Target analysis Target prediction Web server
原文传递
孕产妇脓毒症诊治的研究进展
7
作者 郭飞飞 赖奕欢 王懿春 《中华产科急救电子杂志》 2022年第4期253-256,共4页
脓毒症(sepsis)严重威胁孕产妇生命安全,是导致其死亡的重要原因之一。尽管脓毒症指南经历了多次修改,但国际上均未提出明确统一的孕产妇脓毒症的定义,并且孕产妇脓毒症的诊断标准尚不明确,筛查工具版本繁多,其灵敏度和特异度参差不齐,... 脓毒症(sepsis)严重威胁孕产妇生命安全,是导致其死亡的重要原因之一。尽管脓毒症指南经历了多次修改,但国际上均未提出明确统一的孕产妇脓毒症的定义,并且孕产妇脓毒症的诊断标准尚不明确,筛查工具版本繁多,其灵敏度和特异度参差不齐,加上孕产妇一些生理变化与脓毒症的症状体征重叠,变化多样,使从事产科重症的医护人员难以早期识别和及时治疗,从而延误病情,增加孕产妇发病和死亡风险。现结合脓毒症最新指南,从流行病学、定义、诊断、疾病病因、管理治疗等方面进行综述,总结孕产妇脓毒症诊治研究进展,以期为临床防治工作提供帮助。 展开更多
关键词 死亡风险 症状体征 筛查工具 孕产妇脓毒症 诊断标准 流行病学 早期识别 诊治研究
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部